Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET
Company Participants
Corey Davis - Managing Director, Investor Relations, LifeSci Advisors
Lars Wegner - President and CEO
Bo Karmark - Chief Financial Officer
Conference Call Participants
Thomas Flaten - Lake Street Capital Markets
Operator
Good morning, and welcome to the Evaxion Biotech Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there’ll be an opportunity to ask questions. [Operator Instructions] Please note, that this event is being recorded.
I would now like to turn the conference over to Corey Davis. Please go ahead.
Corey Davis
Thanks, Joe. Hello, everyone. Thanks for joining us this morning. Let me quickly remind everyone that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.
Because forward-looking statements involve risks and uncertainties, they’re not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company’s annual report on Form 20-F, filed on March 31st, 2022, and the company’s current and future reports filed with or submitted to the Securities and Exchange Commission.
At this time, I’m pleased to turn the call over to Lars Wegner, the company’s President and CEO. Lars, take it away.
Lars Wegner
Thank you, Corey. Good morning, everyone. So, thank you for joining us for this Evaxion Biotech Q2 earnings call. I’m Lars Wegner, the Chief Executive Officer of Evaxion, and with me today is; Evaxion’s Chief Financial Officer, Bo Karmark. We’ll give you a short presentation on our business and results, and then open the call up for your questions.
Let
- Read more current EVAX analysis and news
- View all earnings call transcripts